Last reviewed · How we verify
Ga 68 Dotatate (gallium (68Ga) edotreotide)
Ga 68 Dotatate (generic name: gallium (68Ga) edotreotide) is a drug developed by Uihc Pet Imaging. It is currently FDA-approved (first approved 2019) for Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate.
Ga 68 Dotatate, developed by UIHC PET IMAGING, is a small molecule targeting the Somatostatin receptor type 2. It is used for Positron Emission Tomography with Computed Tomography of the whole body, and was FDA approved in 2019. Ga 68 Dotatate is a commercial product with its ownership retained by UIHC PET IMAGING, and its exact commercial status is not specified. Key safety considerations include the standard precautions for PET imaging. It is used to treat conditions that express the Somatostatin receptor type 2.
At a glance
| Generic name | gallium (68Ga) edotreotide |
|---|---|
| Sponsor | Uihc Pet Imaging |
| Target | Somatostatin receptor type 2 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2019 |
| Annual revenue | 305 |
Approved indications
- Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate
Common side effects
Key clinical trials
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors (EARLY_PHASE1)
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma (PHASE1,PHASE2)
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy (PHASE2)
- 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (PHASE2)
- Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery (PHASE1)
- Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ga 68 Dotatate CI brief — competitive landscape report
- Ga 68 Dotatate updates RSS · CI watch RSS
- Uihc Pet Imaging portfolio CI
Frequently asked questions about Ga 68 Dotatate
What is Ga 68 Dotatate?
What is Ga 68 Dotatate used for?
Who makes Ga 68 Dotatate?
What is the generic name of Ga 68 Dotatate?
When was Ga 68 Dotatate approved?
What development phase is Ga 68 Dotatate in?
What is Ga 68 Dotatate's annual revenue?
What does Ga 68 Dotatate target?
Related
- Target: All drugs targeting Somatostatin receptor type 2
- Manufacturer: Uihc Pet Imaging — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate
- Compare: Ga 68 Dotatate vs similar drugs
- Pricing: Ga 68 Dotatate cost, discount & access